A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)
Clinical trial NCT04737330 · TERMINATED
Trial details
- NCT number
- NCT04737330
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-29
- Primary completion
- 2023-05-16
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.